Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chugai
Pharma
OX40, Roche-Sanegene, Daiichi—Fierce Pharma Asia
Amgen returned Kyowa's OX40 drug. Roche inked an RNAi deal with Sanegene. Daiichi discontinued its first non-DXd candidate. And more.
Angus Liu
Feb 6, 2026 9:48am
Astellas, Takeda, Chugai and more—Fierce Pharma Asia
Jan 23, 2026 9:05am
Takeda, Innovent-Lilly, Roche—Fierce Pharma Asia
Oct 31, 2025 8:20am
Chugai strikes $200M deal for IgAN asset in Asian countries
Oct 24, 2025 9:40am
Licensing deals, Nkarta CEO comments and more—Fierce Pharma Asia
Oct 24, 2025 8:30am
Lilly-Innovent, Dizal, bispecific ADC—Fierce Pharma Asia
Jul 10, 2025 5:20pm
